ipsc cell lines atcc acs 1004  (ATCC)

Journal: Molecular Therapy. Nucleic Acids

Article Title: Efficient Gene Editing at Major CFTR Mutation Loci

doi: 10.1016/j.omtn.2019.02.006

Figure Lengend Snippet: Establishment of Gene-Corrected and Compound Mutation iPSC Lines from dF/dF Patient-Derived iPSCs (A) Efficiencies in generating heterozygously (dF/CT) and homozygously (CT/CT) corrected iPSC clones from a patient- (dF/dF) derived iPSC line. (B) Immunofluorescent staining of pluripotency markers in iPSCs. Scale bar, 100 μm. (C) Expression of pluripotency genes in iPSCs. Data are presented as mean ± SEM. (D) Germlayer-specific transcript levels in EBs derived from iPSC lines. Data are presented as mean ± SEM. (E) Efficiencies in generating G551D mutation clones from a dF/CT iPSC line. (F) Percentage of clones that carry the G551D/dF heterozygous compound mutations among four heterozygous G551D clones.

Article Snippet: A patient-derived iPSC line (ACS-1004, ATCC) carrying the homozygous dF mutation was used. sg06-dF, which has been validated with greater than 80% indel rates ( C), was used as the targeting gRNA.

Techniques: Mutagenesis, Derivative Assay, Clone Assay, Staining, Expressing